Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Letter to the Editor

Tissue doppler echocardiography detects preclinical markers of cardiac lesion in MDS patients

Authors: Cláudio César Monteiro de Castro, Carlos Bellini Gondim Gomes, Manoel Ricardo Alves Martins, Juliana Cordeiro de Sousa, Silvia MM Magalhaes, Ronald F Pinheiro

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder of elderly people. Cardiac dysfunction is a marker of grim prognosis in MDS. We evaluated cardiac dysfunction of MDS patients with or without transfusion dependency by tissue doppler echocardiography. We found the average values of ventricular end-systolic and end-diastolic volumes in transfusion dependency MDS group higher than others. These results were strongly correlated to hemoglobin levels. Tissue Doppler Echocardiography should be routinely performed in MDS patients to detect preclinical cardiac alterations and prevent more heart insults in this group of chronic anemic aged patients.
Appendix
Available only for authorised users
Literature
1.
Cazzola M, Della Porta MG, Travaglino E, Malcovati L: Classification and prognostic evaluation of myelodysplastic syndromes. Semin Oncol. 2011, 38 (Suppl 5): 627-634.CrossRefPubMed
2.
Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME: Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011, 29: 2240-2246. 10.1200/JCO.2010.31.3353.PubMedCentralCrossRefPubMed
3.
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005, 20 (Suppl 30): 7594-7603.CrossRef
4.
Carmer R: Anemia and aging: an overview of clinical, diagnostic and biological issues. Blood Rev. 2001, 15: 9-18. 10.1054/blre.2001.0146.CrossRef
Metadata
Title
Tissue doppler echocardiography detects preclinical markers of cardiac lesion in MDS patients
Authors
Cláudio César Monteiro de Castro
Carlos Bellini Gondim Gomes
Manoel Ricardo Alves Martins
Juliana Cordeiro de Sousa
Silvia MM Magalhaes
Ronald F Pinheiro
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-30

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue

Letter to the Editor

Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia

Research

Correlation of SRSF1 and PRMT1 expression with clinical status of pediatric acute lymphoblastic leukemia

Review

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

Research

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

Review

Acute graft versus host disease after orthotopic liver transplantation

Research

Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits